CION Ameerpet
Other Immune Therapies
Therapeutic Cancer Vaccines — What Exists Today
A therapeutic cancer vaccine is given to someone who already has cancer, to teach the immune system to recognise their tumour. The category is real. A small number of products are approved in a few countries for narrow situations, and in India almost none of it is routine treatment. This page follows NCCN, ESMO and WHO patient-education framing to say plainly what exists, what is only in trials, and what you cannot get here.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Real, but rare — the category exists and holds approvals in a handful of countries for narrow indications, but it is not treatment you can simply ask for
- India availability, stated plainly — what is standard here, what is approved but not standard, and what is trial-only, with no vague language and no implied access
- Classes and mechanisms only — no product or molecule names, no efficacy claims and no comparison between products, because approval status differs by country and changes
- Written for people being sold something — the six checks that separate a registered clinical trial from a brochure with a price on it
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start Here
Do therapeutic cancer vaccines actually exist?
Yes. They are a real category of treatment, not a myth. A small number carry regulatory approval in a few countries, each for a narrow situation. But almost everything you read about in headlines is still being tested in trials, and very little of this category is routine cancer treatment in India today.
That gap — between how much is written about therapeutic cancer vaccines and how little you can actually receive — is the whole subject of this page. The science is genuinely interesting. The availability is genuinely thin. Both things are true at once, and most pages you will find online tell you only one of them.
A therapeutic cancer vaccine is given to a person who already has cancer. It is meant to show the immune system a protein carried by that tumour, so that immune cells learn to find it. That is a completely different thing from the vaccines that prevent cancer by preventing a virus — those are given to healthy people, and are covered in HPV and Hepatitis B Vaccination: Preventing Cancer, Not Treating It. Mixing the two up is the single most common error in this subject.
This page describes classes and mechanisms only. It names no products and no molecules, makes no comparison of how well one works against another, and states where the evidence is immature rather than papering over it. Approval status differs from country to country and changes, so every status line here is written as of August 2026 and should be confirmed with your treating oncologist.
Did you know?
The word “vaccine” is doing two completely different jobs in cancer care. The vaccines that have already saved lives from cancer are vaccines against viruses — WHO attributes nearly all cervical cancer to persistent high-risk HPV infection, and long-term hepatitis B infection is a leading cause of liver cancer. Those are given to healthy people. A therapeutic cancer vaccine is a different proposition entirely: given after a diagnosis, aimed at the tumour itself, and still mostly investigational.
Approval Status
Which therapeutic cancer vaccines are approved, and where?
Only a handful, and mostly not in India. Two approaches hold approvals in some Western countries for narrow indications: an autologous cell-based immunotherapy for advanced prostate cancer, and an injected oncolytic viral therapy for certain melanoma lesions. Within India, one autologous dendritic-cell preparation carries a national regulatory approval for a small set of refractory solid tumours.
Framing follows NCCN, ESMO and WHO patient-education material. Classes are named, products are not, and no efficacy comparison is made between them. Approval status is country-specific and changes — confirm the current position with CDSCO and your treating oncologist before acting on anything in this table.
India, Specifically
What can you actually get in India today?
Very little of this category, and none of it as standard treatment. What genuinely exists here is BCG into the bladder, one approved autologous dendritic-cell preparation at a small number of centres, and registered clinical trials. Everything else is either approved only abroad, or is being sold to you as something it is not.
Available · Standard care
BCG into the bladder
A live attenuated bacterial vaccine strain, placed directly into the bladder for early, non-muscle-invasive bladder cancer. It is a local immune stimulant, not a tumour-specific vaccine, and it is routine, established treatment in India.
Approved · Not standard
An autologous dendritic-cell preparation
Holds an Indian approval for a narrow set of refractory solid tumours and is offered privately at a few centres. It is not in standard treatment pathways and the evidence base is limited. See Dendritic Cell Therapy: Evidence and Availability in India.
Reachable · Through your team
A registered clinical trial
Trials are listed on India's Clinical Trials Registry and on international registries. Entry is arranged through your treating oncologist, at a participating site, on defined eligibility criteria.
Not available
Products approved only abroad
An approval in another country does not make a product purchasable here. Named-patient import is a regulated, slow and expensive route, needs your oncologist to drive it, and is rarely appropriate.
Sold · Not the same thing
“Immunity” injections and drips
Immune-boosting injections, drips and cell preparations marketed outside a trial are not therapeutic cancer vaccines, whatever the brochure calls them. Ask for the regulatory approval and the trial registration in writing, before any payment.
Immunotherapy at CION is given as day care, and the immunotherapy that is standard treatment in India today is a different class altogether — explained on the Immunotherapy at CION Cancer Clinics hub.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Check it with an oncologist before you pay for it
Bring us the brochure, the WhatsApp forward or the trial name. A CION medical oncologist will tell you what it is, where it stands, and whether it relates to your diagnosis at all.
Still Being Tested
What is in trials right now?
Most of the field. Individualised neoantigen vaccines, mRNA delivery, peptide vaccines, dendritic-cell vaccines and viral-vector approaches are all in active trials, many of them paired with a checkpoint inhibitor. Results so far are mixed, long-term benefit is not established, and none of it is approved treatment you can request.
Individualised neoantigen vaccines
The tumour is sequenced, mutations unique to that one patient are identified, and a vaccine is manufactured against them. Late-stage trials are running internationally. Manufacturing time and cost are the practical obstacles.
mRNA cancer vaccines
Genetic instructions are delivered so the body makes the target protein itself. This is the approach behind most of the headlines. mRNA Cancer Vaccines: What the Headlines Actually Mean covers it properly.
Peptide vaccines
Short fragments of a tumour protein given with an adjuvant. One of the oldest approaches in the field, studied for decades.
Dendritic-cell vaccines
The patient's own antigen-presenting cells are loaded in a laboratory and returned. The one part of the category with an Indian approval, in a narrow indication.
Viral-vector and whole-cell vaccines
A harmless virus, or whole inactivated tumour cells, used as the delivery vehicle. Long-studied, with mixed results across tumour types.
Vaccine plus checkpoint inhibitor
Much current research combines the two, on the logic that a vaccine supplies the target while a checkpoint inhibitor releases the brake that stops T cells acting. Still under investigation.
Evidence in this field is genuinely immature. Durability of response, exactly which patients benefit, and late immune-related effects are all still being worked out, and honest sources say so. No efficacy figures are quoted on this page for that reason.
Before You Pay Anyone
How do you tell a genuine trial from a sales pitch?
Ask for paperwork, in writing, before money moves. A registered trial has a registry number you can look up, a written consent document, and a treating team you can name. A sales pitch has testimonials, urgency, and a price. Six checks separate the two.
-
Ask for the trial registration number
In India that means a CTRI number; internationally, a registry identifier. Look it up yourself. If nobody can give you one, it is not a clinical trial.
-
Ask what regulatory approval it holds
Which authority, which country, which indication, and in writing. “Approved abroad” is not an answer. An approval elsewhere does not make something lawful or appropriate treatment here.
-
Ask who is paying for the product
In most registered trials the investigational product is not billed to you. A large upfront payment for an “experimental vaccine” is a strong signal that you are being sold something, not enrolled in research.
-
Read the informed consent document
A real trial hands you a written consent form describing the purpose, the procedures, the risks and your right to withdraw. Take it home. Nobody serious will rush you through it.
-
Take it to your treating oncologist first
Trial entry is arranged through your team, not around it. Your oncologist can check eligibility, spot an interaction with what you are already receiving, and read the protocol you cannot.
-
Do not stop your current treatment to chase it
This is where the real harm happens. Keep your planned treatment running while you check anything new. A delay of weeks, taken on a brochure, is a decision with consequences.
Related Reading
Where to go next on this subject
- mRNA Cancer Vaccines: What the Headlines Actually Mean — the approach behind most of the news coverage, and what stage it has genuinely reached.
- Dendritic Cell Therapy: Evidence and Availability in India — the one part of this category with an Indian approval, and what the evidence behind it does and does not show.
- HPV and Hepatitis B Vaccination: Preventing Cancer, Not Treating It — the vaccines that already prevent cancers, which are a different thing entirely from this page.
- Immunotherapy at CION Cancer Clinics — the hub page, covering the immunotherapy that is standard treatment in India: eligibility, biomarker testing, day-care administration and cost.
This page is general information and does not replace a consultation. It names drug classes and mechanisms only, not products, and makes no efficacy claim or comparison. Regulatory status is stated as understood in August 2026 and changes over time — verify current status with CDSCO and with your treating oncologist before making any decision.
You are not the first to ask
Families bring us these offers almost every week
It is a fair question and it deserves a straight answer, not a brush-off. Our team will take the time to explain what exists, what is being tested, and what is simply being sold.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Therapeutic cancer vaccines: your questions answered
Is a therapeutic cancer vaccine available in India?
Not as routine cancer treatment. As of August 2026 there is no therapeutic cancer vaccine that sits inside standard Indian cancer care the way chemotherapy, radiation or checkpoint immunotherapy does. Three things do exist here. BCG placed into the bladder for early bladder cancer, which is an immune stimulant rather than a tumour-specific vaccine. One autologous dendritic-cell preparation that has held an Indian regulatory approval for a narrow set of refractory solid tumours, offered at a small number of centres and not part of NCCN or ESMO standard pathways. And registered clinical trials. Anything else being offered to you should be checked in writing before you pay.
Do therapeutic cancer vaccines actually exist, or is it only research?
They exist. A therapeutic cancer vaccine is given to a person who already has cancer and is designed to teach their immune system to recognise proteins carried by the tumour. That is a real category of medicine, not a myth, and a small number of products have regulatory approval in some countries for narrow indications. The honest summary is that the idea is real, the approvals are few, and the availability in India is very limited. Most of what appears in headlines is still being tested in clinical trials and is not treatment you can request.
Which therapeutic cancer vaccines are approved anywhere in the world?
Only a handful, and each for a narrow situation. An autologous cell-based immunotherapy is approved in some Western countries for advanced prostate cancer in specific circumstances. An injected oncolytic viral therapy is approved in some countries for certain melanoma skin and lymph node lesions. In India, one autologous dendritic-cell preparation carries a national regulatory approval for a small group of refractory solid tumours. This page names classes and mechanisms rather than products, because approval status is country-specific, changes over time, and comparing branded products is not appropriate on a patient-education page.
What therapeutic cancer vaccines are in clinical trials?
Several approaches are in active trials worldwide. Individualised neoantigen vaccines sequence one patient's tumour and build a vaccine against mutations unique to it. mRNA vaccines deliver genetic instructions so the body makes the target protein itself. Peptide vaccines give fragments of tumour protein with an adjuvant. Dendritic-cell vaccines load the patient's own antigen-presenting cells in a laboratory. Viral-vector and whole-tumour-cell approaches have been studied for decades. Many trials now pair a vaccine with a checkpoint inhibitor. Results so far are mixed, long-term benefit is not established, and none of this is approved treatment.
Is dendritic cell therapy the same as a therapeutic cancer vaccine?
It belongs to the same family. Dendritic cells are the immune cells whose job is to show a target to T cells, so loading them with tumour material in a laboratory and returning them to the patient is one way of building a therapeutic cancer vaccine. In India this is the one part of the category with a regulatory approval, for a narrow set of refractory solid tumours, and it is offered privately at a small number of centres. It is not part of standard treatment pathways, the evidence base behind it is limited, and it should be discussed with your treating oncologist before any commitment.
Can a therapeutic cancer vaccine replace the treatment I am already on?
No. Nothing on this page is an alternative to surgery, chemotherapy, radiation or the immunotherapy your oncologist has planned. Where these products are approved at all, they are used in narrow situations, usually alongside or after standard treatment, and always on a specialist decision rather than a patient's own. The most common way this subject causes harm is a family stopping or delaying an evidence-based treatment while they arrange something they read about online. If a trial or a product interests you, raise it with your treating team first, and keep your current treatment running while you check it.